by Gene and cell therapies targeting CNS disorders involve the use of gene editing tools, cell-based therapies, and biomaterials to develop therapeutic interventions for treating complex neurological conditions. Diseases affecting the central nervous system (CNS) like Alzheimer’s, Parkinson’s, cerebral palsy, and epilepsy are becoming more prevalent globally due to aging population and other risk factors. These therapies aim to replace mutated genes, develop new cells to replace damaged ones, or modify cell and tissue microenvironments in the CNS to improve outcomes for patients.
The global gene and cell therapies targeting CNS disorders Market is estimated to be valued at US$ 8.2 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing prevalence of neurodegenerative diseases is one of the major drivers for the growth of gene and cell therapies targeting CNS disorders market. As per the given market report, over 50 million people are suffering from Alzheimer’s disease worldwide in 2022 and this number is expected to triple by 2050. Similarly, Parkinson’s disease burden is also rising substantially driven by aging population. Furthermore, significant investments in R&D for developing new gene therapy products is also propelling the market growth. Both private and public organizations are funding projects exploring gene editing tools like CRISPR for treating neurological conditions. Lastly, ongoing clinical trials evaluating safety and efficacy of various cell-based therapies for disorders like amyotrophic lateral sclerosis and multiple sclerosis provide promising opportunities in the market over the forecast period.
Segment Analysis
The global gene and cell therapies targeting CNS disorders market is segmented based on gene therapy type, cell therapy type, therapeutic area, and end user. The gene therapy segment is further segmented into viral vector gene therapy and non-viral vector gene therapy. Viral vector gene therapy dominates the gene therapy segment due to its high efficiency in delivering therapeutic genes into target cells. The cell therapy segment is further segmented into stem cell therapy and cell surface marker therapy. Stem cell therapy dominates the cell therapy segment owing to the wide scope of applications of stem cell-based therapies in treating CNS disorders.
PEST Analysis
Political: Governments across the world are increasing funding for research activities related to gene and cell therapies targeting CNS disorders. For instance, the US National Institutes of Health invested over USD 2 Bn in 2020 for brain research.
Economic: Rising incidence of CNS disorders and growing need for advanced treatment options is driving the growth of this market. However, high costs associated with R&D and product development may hamper market growth.
Social: Growing awareness about various CNS disorders and clinical benefits of gene and cell therapies is positively impacting the adoption of these therapies. However, ethical issues related to gene editing and cell therapies may impede market growth.
Technological: Significant advancements in gene therapy vectors, stem cell biology research, and bioengineering are creating opportunities for development of innovative gene and cell therapies for CNS disorders. Computational tools for gene and cell therapies design are also enhancing R&D activities.
Key Takeaways
Global Gene And Cell Therapies Targeting CNS Disorders Market Size is expected to witness high growth during the forecast period. North America dominates the market currently due to rapid adoption of advanced therapies and presence of prominent market players in the region. Key players operating in the gene and cell therapies targeting CNS disorders market are Sophion Bioscience A/S, Nanion Technologies GmbH, NeoBiosystems, Inc., Multi Channel Systems MCS GmbH, Fluxion Biosciences, Molecular Devices, LLC, Scitech Korea Inc., and HEKA Elektronik GmbH.
Regional analysis
North America holds the major share of the global gene and cell therapies targeting CNS disorders market. This is attributed to growing incidence of neurological disorders, rising geriatric population, availability of research funding, presence of advanced healthcare infrastructure, and adoption of advanced treatment options for CNS disorders. For instance, in 2020, the US witnessed around USD 2 Bn investment by the National Institutes of Health for brain research and development activities.
Key players
Key players operating in the gene and cell therapies targeting CNS disorders market are Sophion Bioscience A/S, Nanion Technologies GmbH, NeoBiosystems, Inc., Multi Channel Systems MCS GmbH, Fluxion Biosciences, Molecular Devices, LLC, Scitech Korea Inc., and HEKA Elektronik GmbH. These players are focusing on new product launches, collaborations, and geographic expansion to strengthen their market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
